From Patient Biology to Patient Benefit.
Bridging breakthrough discoveries in patient-derived biology with meaningful clinical impact, our mission is to develop a first-in-class, brain-penetrant small-molecule therapy that slows or halts disease progression in people living with Parkinson's disease.
Patient Centred
The scientific breakthrough behind our program emerged from large-scale AI-enhanced phenotypic screening of patient-derived dopaminergic neurons, identifying a chemical hit that significantly reduced alpha-synuclein while preserving neuronal health.
Novel Biology
Our target is part of a previously unexplored intracellular alpha-synuclein clearance pathway, operating independently of known lysosomal and proteasomal mechanisms. This differentiated biology underpins our first-in-class therapeutic approach.

Oral Therapy
Our small-molecule lead compounds are optimized for high potency, brain penetration and safety. Supported by first in vivo signs of efficacy, they provide a strong foundation for an effective, orally available disease-modifying therapy.
Translation
Activity of our lead compounds has been demonstrated across various patient-derived cellular disease models for Parkinson's Disease. The underlying target has most likely therapeutic relevance beyond Parkinson’s disease, supporting future expansion into additional indications to be explored.
Building the next chapter of Parkinson's innovation together.
We welcome conversations with scientists, clinicians, investors, patient organizations, and potential partners who share our commitment to improving the lives of people living with Parkinson’s disease.



